EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • Texas
This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of December 5, 2019 (the “Effective Date”), by and between Shattuck Labs, Inc. (the “Company”) and Taylor Schreiber (“Executive”).
Shattuck Labs, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
EXCLUSIVE LICENSE AGREEMENT By and between Shattuck Labs, Inc. and Heat Biologics, Inc. Effective as of June 3, 2016Exclusive License Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”), effective this 3rd day of June, 2016 (the “Effective Date”), is between Shattuck Labs, Inc., a Delaware corporation (“Shattuck”), and Heat Biologics, Inc., a Delaware corporation (“Heat”). Shattuck and Heat are each a “Party” and collectively the “Parties.”
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 (the “Amendment”) is entered into as of this 27th day of March, 2020 by and between Shattuck Labs, Inc. (the “Company”) and Taylor Schreiber (the “Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and the Executive.
SHATTUCK LABS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of June 12, 2020 by and among Shattuck Labs, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder,” and any other Person that becomes a party to this Agreement in accordance with Section 7.14 hereof.
SHATTUCK LABS, INC. and MILLENNIUM PHARMACEUTICALS, INC. COLLABORATION AGREEMENT Effective as of August 8, 2017Collaboration Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Collaboration Agreement (this “Agreement”), effective this 8th day of August, 2017 (the “Effective Date”), is between Millennium Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Millennium”), and Shattuck Labs, Inc., a Delaware corporation having its principal place of business at 3317 Bowman Avenue, Austin, TX 78703 (“Shattuck”). Millennium and Shattuck are each sometimes referred to herein as a “Party” and collectively as the “Parties.”
LEASE AGREEMENT BETWEEN PARMER RTP, LLC, AS LANDLORD, AND SHATTUCK LABS, INC., AS TENANT DATED APRIL 17, 2018 DURHAM, NORTH CAROLINALease Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • Texas
This Lease Agreement (this “Lease”) is entered into as of April ____, 2018, between PARMER RTP, LLC, a Delaware limited liability company (“Landlord”), and SHATTUCK LABS, INC., a Delaware corporation (“Tenant”).
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations
This AMENDMENT NO. 1 (the “Amendment”) is entered into as of this 27th day of March, 2020 by and between Shattuck Labs, Inc. (the “Company”) and Josiah C. Hornblower (the “Executive”) and amends that certain Employment Agreement dated as of December 5, 2019 (the “Agreement”) between the Company and the Executive.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Master Services AgreementMaster Services Agreement • September 18th, 2020 • Shattuck Labs, Inc. • Pharmaceutical preparations • New York
This Master Services Agreement (this “Agreement”) dated March 31, 2017 (the “Effective Date”), between Shattuck Labs, Inc., having a place of business at 3317 Bowman Ave, Austin, TX 78703 (“Client”) and KBI Biopharma, Inc., having a place of business at 1101 Hamlin Road, Durham, North Carolina 27704 (“KBI Biopharma”) (Client and KBI Biopharma, each a “Party”, and collectively, the “Parties”).
